Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.


NDAQ:PMN - Post by User

Bullboard Posts
Post by jjwilsonon Jun 21, 2016 10:07pm
233 Views
Post# 24985838

For those new to PMN....

For those new to PMN....
Random comments from an anonymous person on Stockhouse probably don't count for much but I'll post them anyways.  I'm long.  Not just a little long but reallly long - bought my first shares in Amorfix, which became Promis, something like 8 or 9 years ago.

Whether you sell or not makes no difference to me and I know it's tempting to sell and take the quick cash.  I know because I have done the same thing with other companies - if the share price doubles in a week it's hard not to sell.  The thing to realize is that this isn't some junior mining company that's limited by the resource on the property or some company like BBD that's limited by how many planes it can sell.  The upside potential here is absolutely huge and we haven't even scratched the surface.  The intellectual property will ultimately be worth billions (in my opinion, of course) so do the math - 1 billion dollars divided by 170 million shares = $5.88/share!  That's 30 times higher than the 19.5  cent close today!  Obviously I can't guarantee that will happen.  Maybe we get bought out for less, who knows what will happen but you should know that many of the longs, such as myself, expect that share price to go much, much higher. 

The price might go down tomorrow - don't know.  Sell if you want to pocket the quick cash but before you do I suggest you spend some time on the Promis website - watch the presentations and read the pdfs. 
Bullboard Posts